课题基金 / 基金详情

IRSG LABORATORY CORRELATIVE STUDIES

IRSG LABORATORY CORRELATIVE STUDIES
IRSG 实验室相关研究
批准号:
2896796
负责人:
FREDERIC G BARR
金额:
$19.62万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-09-01 至 2001-08-31

项目摘要

项目成果

FREDERIC G BARR的其他基金

相关文献

中文摘要
翻译
小儿横纹肌肉瘤的组织学分类 已建立的亚型与不同的临床 特色 加强了亚型之间的区别 通过分子研究发现,PAX 3/PAX 7-FKHR基因融合在 在胚胎期的肺泡RMS和染色体区域11p15.5的等位基因丢失 RMS。 尽管该分类系统的实用性,临床 在这些亚型中, 阶段和结果。 作为这种异质性的潜在相关物, 其他原癌基因和肿瘤抑制基因的改变已经被 在较小的RMS肿瘤子集中检测到。 特别是, p53和RAS基因,MYCN和12 q13 -15基因座扩增,以及 在RMS病例中已经报道了CDKN 2A的缺失。 其中一些 变化优先发生在单个亚型中,而其他亚型 在所有亚型中均发生低频率的改变。这些发现 表明RMS发病机制可以被表征为多步骤 一个涉及基本亚型特定事件的过程, 与其他亚型特异性和非特异性事件。 的发生 每个RMS亚型的仅一个子集中的改变提供了以下基础: 这些类别中的遗传异质性可能提供了一个 临床异质性的解释。 在本申请中, 横纹肌肉瘤研究组(IRS) 将研究p53和RAS家族突变的临床意义, MYCN和12 q13 -15扩增,以及CDKN 2A改变 从密切监测的 并对IRS试验的患者进行统一治疗。 我们尤其 将检测这些基因改变中的每一种以及PAX 3/PAX 7- 从IRS-IV到IRS-IV的一组98份冷冻肿瘤样本中的FKHR融合状态 建立总体频率和与病理和 这些病例的临床特点。 根据这些发现, 具体的协会将进一步审查的直接分析, 在来自美国的选定肿瘤标本中的特异性遗传改变 收集了900多个IRS-III石蜡块。 这些研究将 提供对发生率和临床 这些遗传改变在RMS中意义,并鉴定新的 这些标记物将在前瞻性IRS研究中进一步分析。
英文摘要
Histopathologic classification of pediatric rhabdomyosarcoma (RMS) has established subtypes that are associated with distinct clinical characteristics. The distinction between the subtypes is strengthened by molecular studies that identified PAX3/PAX7-FKHR gene fusions in alveolar RMS and allelic loss of chromosomal region 11p15.5 in embryonal RMS. Despite the utility of this classification system, clinical heterogeneity exists within these subtypes in such parameters as site, stage, and outcome. As a potential correlate of this heterogeneity, alterations of other prot-oncogenes and tumor suppressor genes have been detected in smaller subsets of RMS tumors. In particular, mutations of p53 and RAS genes, amplification of MYCN and 12q13-15 loci, and deletions of CDKN2A have been reported in cases of RMS. Some of these changes occur preferentially in a single subtype whereas other alterations occur at a low frequency in all subtypes. These findings indicate that RMS pathogenesis can be characterized as a multistep process involving fundamental subtype-specific events that collaborate with other subtype-specific and non-specific events. The occurrence of alterations in only a subset of each RMS subtype provides the basis for genetic heterogeneity within these categories that may provide an explanation for clinical heterogeneity. In this application, the Biology Committee of the Intergroup Rhabdomyosarcoma Study (IRS) Group will examine the clinical significance of p53 and RAS family mutations, MYCN and 12q13-15 amplification, and CDKN2A alterations in a large panel of well-characterized RMS tumors collected from the closely monitored and uniformly treated patients of the IRS trials. In particular, we will assay for each of these genetic alterations as well as PAX3/PAX7- FKHR fusion status in a set of 98 frozen tumor samples from IRS-IV to establish the overall frequencies and associations with pathologic and clinical characteristics of these cases. Based on these findings, specific associations will be further examined by directed analysis of specific genetic alterations in selected tumor specimens from the collection of over 900 paraffin blocks of IRS-III. These studies will provide a definitive analysis of the occurrence and clinical significance of these genetic alterations in RMS, and identify novel markers that will be analyzed further in prospective IRS studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DNA methylation-based assays for detecting disease spread in rhabdomyosarcoma
  • 批准号:
    7875543
  • 项目类别:
  • 资助金额:
    $17.4万
  • 财政年份:
    2010
  • 负责人:
    FREDERIC G BARR
  • 依托单位:
COG studies of gene amplification in rhabdomyosarcoma
  • 批准号:
    7910236
  • 项目类别:
  • 资助金额:
    $13.0万
  • 财政年份:
    2009
  • 负责人:
    FREDERIC G BARR
  • 依托单位:
COG studies of gene amplification in rhabdomyosarcoma
  • 批准号:
    7233681
  • 项目类别:
  • 资助金额:
    $41.37万
  • 财政年份:
    2005
  • 负责人:
    FREDERIC G BARR
  • 依托单位:
COG studies of gene amplification in rhabdomyosarcoma
  • 批准号:
    7431756
  • 项目类别:
  • 资助金额:
    $41.71万
  • 财政年份:
    2005
  • 负责人:
    FREDERIC G BARR
  • 依托单位: